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The discovery of vascular endothelial growth 
factors (VEGFs) and their receptors has facili-
tated the understanding of the development 
and function of the vasculature (1–3). Each 
VEGF family member appears to have a spe-
cifi  c function. Whereas VEGF induces angio-
genesis, i.e., growth of new blood vessels from 
preexisting ones, placenta growth factor (PlGF) 
mediates both angiogenesis and arteriogenesis, 
i.e., the formation of collateral arteries from 
preexisting arterioles (1, 2). VEGF-C and -D 
are primarily lymphangiogenic factors, which 
can also trigger angiogenesis in some condi-
tions (3). Overall, the members of the VEGF 
family and their receptors appear to provide 
promising and versatile tools for therapeutic 
manipulation of the vascular system (1–3).
VEGF is one of the most important regula-
tors of both physiological and pathological 
angiogenesis, and its activity is mediated via 
VEGF receptor (VEGFR) 1 and 2. VEGF, act-
ing mainly via VEGFR-2, is an endothelial cell 
mitogen, motogen, chemoattractant, and sur-
vival factor that increases the permeability of 
blood vessels (1). The importance of VEGF in 
the development of the vascular and hemato-
poietic systems is exemplifi  ed by the fact that 
inactivation of even one VEGF allele leads to 
early embryonic lethality caused by defects in 
angiogenesis and hematopoiesis (4, 5).
Genes with sequence homology to VEGF 
have been discovered in Orf and   pseudocowpox 
Distinct vascular endothelial growth factor 
signals for lymphatic vessel enlargement 
and sprouting
Maria Wirzenius,1 Tuomas Tammela,1 Marko Uutela,1 Yulong He,1 
Teresa Odorisio,2 Giovanna Zambruno,2 Janice A. Nagy,3 
Harold F. Dvorak,3 Seppo Ylä-Herttuala,4 Masabumi Shibuya,5 
and Kari Alitalo1
1Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Haartman Institute and Helsinki University 
Hospital, Biomedicum Helsinki, University of Helsinki, 00014 Helsinki, Finland
2Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell’Immacolata, Istituto di Ricovero e Cura a Caraterre 
Scientifi  co, 00167 Rome, Italy
3Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215
4A.I. Virtanen Institute, University of Kuopio, 70211 Kuopio, Finland
5Division of Genetics, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan
Lymphatic vessel growth, or lymphangiogenesis, is regulated by vascular endothelial growth 
factor-C (VEGF-C) and -D via VEGF receptor 3 (VEGFR-3). Recent studies suggest that 
VEGF, which does not bind to VEGFR-3, can also induce lymphangiogenesis through 
unknown mechanisms. To dissect the receptor pathway that triggers VEGFR-3–independent 
lymphangiogenesis, we used both transgenic and adenoviral overexpression of placenta 
growth factor (PlGF) and VEGF-E, which are specifi  c activators of VEGFR-1 and -2, 
  respectively. Unlike PlGF, VEGF-E induced circumferential lymphatic vessel hyperplasia, but 
essentially no new vessel sprouting, when transduced into mouse skin via adenoviral vectors. 
This effect was not inhibited by blocking VEGF-C and -D. Postnatal lymphatic hyperplasia, 
without increased density of lymphatic vessels, was also detected in transgenic mice 
expressing VEGF-E in the skin, but not in mice expressing PlGF. Surprisingly, VEGF-E induced 
lymphatic hyperplasia postnatally, and it did not rescue the loss of lymphatic vessels in 
transgenic embryos where VEGF-C and VEGF-D were blocked. Our data suggests that 
VEGFR-2 signals promote lymphatic vessel enlargement, but unlike in the blood vessels, 
are not involved in vessel sprouting to generate new lymphatic vessels in vivo.
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viruses. These virus -encoded VEGFs, which are commonly 
called VEGF-E, cause highly vascularized and pustular dermati-
tis in sheep, in goats, and, occasionally, in humans (6–8). The 
virus-encoded VEGF-Es can be separated into two groups, 
with VEGF-ED1701 and -ENZ2 most closely related to VEGF 
and PlGF, whereas VEGF-ENZ7 is similar to VEGF-C and -D 
(9). In this article, VEGF-E refers to VEGF-ENZ7. The virus-
  encoded VEGFs bind to VEGFR-2 and induce its autophos-
phorylation to almost the same extent as VEGF, but do not bind 
to VEGFR-1 (7, 8, 10). Although VEGF-E does not play a role 
in vascular physiology, it can be used as a VEGFR-2–specifi  c 
agonist in experimental models of angiogenesis in vitro and in 
vivo. Such studies have indicated that VEGF-E expression in the 
skin of transgenic mice results in an angiogenic phenotype (11).
Recent studies have suggested that at least the most com-
monly expressed isoform of VEGF can also induce lymphatic 
hyperplasia (12, 13). However, the signaling mechanisms 
mediating this response have been unclear. In this study, we 
wanted to determine if signals mediated via VEGFR-1 or -2 
can trigger lymphangiogenesis in embryonic or adult tissues. 
For our analysis, we used adenoviral transduction of VEGF-E, 
as well as transgenic overexpression of PlGF and VEGF-E, to 
activate VEGFR-1 and -2, respectively.
RESULTS
Characteristics of VEGF-induced lymphatic hyperplasia
VEGF-C has been shown to induce excessive sprouting 
of lymphatic vessels 4 d after adenoviral delivery and new 
lymphatic vessels after 14 d (14, 15). To study the lymphatic 
vascular eff  ects of VEGF, we transduced the ear skin of mice 
with AdVEGF164 or AdVEGF165, encoding the mouse and 
human isoforms, respectively, and performed whole-mount 
immunofl  uorescence analysis 4 d later. As a positive con-
trol for lymphangiogenesis, we used AdVEGF-C (Fig. 1 A). 
Consistent with the data of Nagy et al. (12), we detected 
enlarged lymphatic vessels and small lymphatic vessel sprouts 
in the skin of AdVEGF164-transduced ears (Fig. 1 B). In 
contrast, lymphatic hyperplasia, but no sprouting, was ob-
served in the AdVEGF165- transduced ears (Fig. 1 C) com-
pared with ears transduced with AdLacZ (Fig. 1 D). These 
experiments indicated that human VEGF165 is capable of 
stimulating only circumferential lymphatic vessel growth, 
whereas mouse VEGF164 induced some lymphatic vessel 
sprouting as well. This diff  erence between the two factors 
was not caused by an increased infl  ammatory response, as 
we detected similar numbers of CD11b+ infl  ammatory cells 
in the AdVEGF164- and AdVEGF165-transduced ears (un-
published data).
Extension and maintenance of tip cell fi  lopodia in the 
blood vascular endothelium has been shown to depend 
on VEGF signaling via VEGFR-2 (16). To determine if 
VEGFR-2 is also needed for the sprouting of lymphatic ves-
sels in adults, we fi  rst injected mice intraperitoneally with 
blocking monoclonal antibodies against VEGFR-2 or -3, 
and then stimulated sprouting of the lymphatic vessels with 
AdVEGF-C, AdVEGF164, or AdVEGF165. Quantifi  cation 
Figure 1.  VEGF- and receptor-specifi  c signals for lymphatic 
  hyperplasia and sprouting. Whole-mount staining for LYVE-1 of indicated 
adenovirus vector-transduced ears. For comparison, AdVEGF-C–induced 
active sprouting and enlargement of the lymphatic vessels (A). Ad-
VEGF164 also induces lymphatic sprouting (B), but AdVEGF165-trans-
duced ears show only circumferential growth of the lymphatic vessels (C) 
in comparison with AdLacZ-transduced ears (D). Arrowheads indicate sites 
of sprouting. Quantitation of the number of lymphatic sprouts in the 
indicated adenovirus vector–transduced ears (E). Note that sprouting of 
lymphatic vessels after VEGF-C transduction is blocked by intraperitoneally 
injected blocking antibodies against VEGFR-3 (mF4-31C1, red bars), but 
not by antibodies against VEGFR-2 (DC101, black bars). The VEGF164-
induced sprouting is blocked by intraperitoneally injected blocking anti-
bodies both against VEGFR-2 (DC101) and -3 (mF4-31C1). No sprouting 
can be detected after VEGF165 or LacZ transduction with or without anti-
body treatment. Quantitation of the PECAM-1–positive vessel density in 
the indicated adenovirus vector-transduced ears (F). The asterisks indicate 
signifi  cantly increased amounts of lymphatic sprouts (E) and signifi  cantly 
increased vessel density areas (F). *, P < 0.05; **, P < 0.01. Results repre-
sent the means ± the SD of six mice per group. Bar, 150 μm.JEM VOL. 204, June 11, 2007  1433
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of lymphatic sprouting showed that the sprouts induced by 
AdVEGF-C were not inhibited by nonspecifi  c rat IgG or 
antibodies against VEGFR-2 (DC101; Fig. 1 E), but were 
strongly inhibited (16-fold) by antibodies against VEGFR-3 
(mF4-31C1). Both antibodies blocked the considerably weaker 
sprouting induced by AdVEGF164, whereas essentially no 
sprouting was obtained after AdVEGF165 or AdLacZ trans-
duction. Quantifi  cation of the platelet endothelial cell ad-
hesion molecule (PECAM) 1–positive vessel density in the 
AdVEGF164- and AdVEGF165-transduced ears indicated 
that both VEGF vectors promoted angiogenesis (Fig. 1 F). In 
contrast, AdVEGF-C or AdLacZ had very little or no eff  ect 
on the blood vessels. Collectively, these results suggested that 
VEGFR-2 signaling may not be necessary for the sprouting 
of lymphatic vessels in adults. To study this further, we chose 
to overexpress VEGF-E in the skin.
VEGF-ENZ7 does not act via the VEGFR-3 pathway
VEGF-E has been shown to bind to VEGFR-2, but not 
to VEGFR-3, in stimulated cells (7, 16). To ensure that 
VEGF-E is not able to induce phosphorylation of VEGFR-3 
in endothelial cells, we stimulated porcine aortic endo-
thelial (PAE) cells stably expressing either VEGFR-2 or -3 
with increasing amounts of recombinant VEGF-E and ana-
lyzed receptor phosphorylation. Although VEGF-E induced 
VEGFR-2 phosphorylation at low concentrations, it was not 
able to induce phosphorylation of VEGFR-3, even at high 
concentrations (Fig. S1 A, available at http://www.jem.org/
cgi/content/full/jem.20062642/DC1). Furthermore, soluble 
VEGFR-2-Ig fusion proteins or rat monoclonal antibodies 
against human VEGFR-2 inhibited VEGFR-2 stimulation 
by VEGF-E, whereas VEGFR-3-Ig did not. In contrast, all 
three reagents blocked VEGFR-2 stimulation by VEGF-C 
(Fig. S1 B). These results indicate that VEGF-E does not 
interact with the VEGFR-3 signal transduction pathway 
in vitro.
Adenovirally transduced VEGF-E induces lymphatic 
hyperplasia in vivo
To determine if the VEGFR-2 transduction pathway can 
trigger lymphatic sprouting, we expressed an adenovirus en-
coding VEGF-E in mouse skin and studied the lymphatic 
vessels by whole-mount immunofl   uorescence analysis 4 d 
later. We detected enlarged lymphatic vessels, but no lym-
phatic vessel sprouts in the skin of AdVEGF-E–transduced 
ears (Fig. 2 A, red signal, and 2 K) compared with ears trans-
duced with AdLacZ (Fig. 2 B, red signal). Simultaneous 
PECAM-1 staining of the blood vessels showed excessive 
angiogenesis in AdVEGF-E–transduced ears (Fig. 2 A, green 
signal) whereas AdLacZ had essentially no eff  ect on the blood 
vasculature (Fig. 2 B, green signal).
To determine if the eff  ects of VEGF-E on the lymphatic 
endothelium indirectly involved the VEGFR-3 ligand recep-
tor system, we injected mice with AdVEGFR-3-Ig, express-
ing a VEGF-C and -D “trap” (17). As shown in Fig. 2 C, the 
hyperplasia of lymphatic vessels induced by AdVEGF-E was 
not inhibited by systemic VEGFR-3-Ig delivery. Further-
more, this treatment did not inhibit the lymphatic vessel 
hyperplasia induced by AdVEGF165, whereas it substantially 
decreased lymphangiogenesis induced by AdVEGF-C treat-
ment. However, the lymphatic area density in the VEGF-E–
transduced ears was considerably decreased by anti–VEGFR-2 
treatment (Fig. 2, D, E, and G), but not by anti–VEGFR-3 
treatment (Fig. 2, F and G). Also, the AdVEGF-C–induced 
lymphatic vessel sprouting was inhibited in this experiment 
only by anti–VEGFR-3 blocking antibodies (Fig. 2, H–K).
Figure 2.  VEGFR-2 is not involved in lymphatic vessel sprouting. 
Whole-mount staining for LYVE-1 (red) and PECAM-1 (green) of indicated 
adenovirus vector–transduced ears. Note that AdVEGF-E–transduced ears 
show circumferential growth of the lymphatic vessels and a strong angio-
genic effect in the blood vessels (A) compared with AdLacZ-transduced 
ears (B). (C) Quantitation of the LYVE-1–positive vessel density in the indi-
cated adenovirus vector-transduced ears. No sprouting can be detected 
after VEGF-E transduction with or without antibody treatment, but block-
ing antibodies against VEGFR-2 (DC101) reduces the hyperplasia of the 
lymphatic vessels (D–F). Sprouting of lymphatic vessels can be detected 
after VEGF-C transduction (H). The sprouting is not blocked by intraperi-
toneally injected blocking antibodies against VEGFR-2 (DC101) (I), but is 
blocked by intraperitoneally injected blocking antibodies against VEGFR-3 
(mF4-31C1) (J). Arrowheads indicate sprouts. Quantitation of the LYVE-1–
positive vessel density (G) and the number of lymphatic sprouts (K) in the 
indicated adenovirus vector–transduced ears. The asterisks indicate signi-
ficant differences in vessel density area (C and G) or the amount of 
  lymphatic sprouts (K). *, P < 0.05; **, P < 0.01. Results represent the 
means ± the SD of six mice per group. Bars: (A and B) 300 μm; (D–F 
and H–J) 150 μm.1434  VEGF RECEPTORS IN LYMPHATIC HYPERPLASIA | Wirzenius et al.
Expression of VEGFR-2 and -3 in lymphatic capillaries 
and collecting vessels
Under normal conditions, VEGFR-3 is expressed strongly 
in lymphatic capillaries, whereas VEGFR-2 is expressed pre-
dominantly in blood vessels, but also, to a smaller extent, 
in lymphatic vessels. VEGFR-2 was prominently expressed, 
particularly in lymphatic valves, as seen in Fig. 3. AdVEGF-C 
transduction induced enlargement of the collecting lym-
phatic vessels and disrupted the typical morphology of the 
valve leafl  ets (Fig. 3, A–F). In contrast, AdVEGF-E transduc-
tion did not have major eff  ects on the collecting lymphatic 
vessels or their valves (Fig. 3, G–L). In high magnifi  cation, 
VEGFR-2 internalization could be seen after AdVEGF-
C and -E transduction, but not after AdLacZ transduction 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20062642/DC1, and not depicted). VEGFR-3 was promi-
nently expressed, particularly in the tips of lymphatic sprouts, 
and was internalized in the lymphatic capillaries after Ad-
VEGF-C transduction (Fig. S2, A–C, and not depicted), but 
not after AdVEGF-E or AdLacZ transduction (Fig. S3, G–I 
and M–O). This result confi  rmed that VEGF-E does not in-
teract with the VEGFR-3 signal transduction pathway in 
vivo, and that the eff  ect of VEGF-E on the lymphatic capil-
laries is, at least in part, directly mediated via VEGFR-2.
K14-VEGF-E transgenic mice have hyperplastic lymphatic 
vessels in the skin
To study the role of VEGFR-2 signaling in lymphangiogen-
esis under conditions not involving an infl  ammatory re-
sponse to the adenovirus and minor tissue injury caused by 
vector injection, we next analyzed transgenic mice that ex-
press VEGF-E driven by the keratin 14 (K14) promoter in 
basal epidermal cells (11). These mice were shown to exhibit 
a substantial increase in the blood vessel density of their skin. 
We found by whole-mount staining of lymphatic vessels that 
the transgenic mice also have enlarged cutaneous lymphatic 
capillaries when compared with wild-type mice (Fig. 4, 
A and F). The K14-VEGF-E lymphatic vessels absorbed fl  uo-
rescent dextran from sites of intradermal injection in fl  uores-
cent lymphangiography, indicating that they were functional 
(Fig. S3, A and B). In contrast to the capillaries, the collecting 
lymphatic vessels or vessels in the lymph nodes were not hy-
perplastic in the K14-VEGF-E mice (Fig. S3, A–F). Shown 
for comparison are lymphatic vessels induced by the VEGFR-
3–specifi  c ligand VEGF-C156S (18), which is expressed un-
der the same K14-promoter (Fig. 4 B) (19). It is notable that 
the lymphatic vessels in K14-VEGF-C156S mice were mostly 
located around the hair follicles that produce high levels of 
the transgene-encoded protein, whereas no such relationship 
was apparent in the hyperplastic lymphatic vessels of the K14-
VEGF-E mice. In contrast, the lymphatic vessels in the skin 
of the K14-PlGF mice were similar to those of littermate 
wild-type mice (Fig. 4, C and F).
PlGF coexpression inhibits VEGF-E–induced 
lymphatic hyperplasia
Surprisingly, when we crossed the K14-VEGF-E mice with 
K14-PlGF mice to simultaneously activate VEGFR-1 and - 2 
receptor homodimers, we found that the lymphatic hyper-
plasia induced by VEGF-E was inhibited (Fig. 4 D). Quan-
tifi  cation of LYVE-1–positive vessel area confi  rmed that the 
lymphatic vessels of the compound K14-VEGF-E + K14-
PlGF transgenic mice were considerably less hyperplastic 
than those of K14-VEGF-E mice (Fig. 4 G). Furthermore, 
when adenoviruses expressing AdPlGF and AdVEGF-E 
were injected separately into the ear skin of nude mice, the 
VEGF-E–induced lymphatic hyperplasia was partially halted 
(unpublished data). As the adenoviral vectors in these conditions 
Figure 3.  VEGFR-2 and -3 are expressed in the collecting lym-
phatic vessels and in the valves. Whole-mount stainings for VEGFR-2 
or -3 (red) and PECAM-1 (green) of the indicated adenovirus vector–
  transduced ears. Note that AdVEGF-C transduction enlarges the collecting 
lymphatic vessels (and stimulates internalization of VEGFR-3; A–F and not 
depicted), whereas AdVEGF-E transduction does not have any effect on the 
collecting vessels or the valves (G–L) compared with the AdLacZ-transduced 
ears (M–R). The arrowheads indicate lymphatic valves. Bar, 150 μm.JEM VOL. 204, June 11, 2007  1435
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transduced predominantly nonoverlapping cell populations 
in the skin (unpublished data), the inhibition of lymphan-
giogenesis by PlGF was not dependent on heterodimer 
formation between PlGF and VEGF-E. In contrast, addi-
tional hyperplasia was seen in the lymphatic vessels of the 
compound K14-VEGF-E + K14-VEGF-C156S transgenic 
mice that should activate both VEGFR-2 and -3 receptor 
homodimers (Fig. 4 E). No considerable diff  erences were 
detected in the accumulation of CD11b-positive infl  am-
matory cells in the skin of K14-VEGF-E mice in compari-
son to K14-PlGF mice, which is consistent with the idea 
that the lymphatic phenotype in the K14-VEGF-E mice 
is not caused by infi  ltration of infl  ammatory cells produc-
ing VEGF-C or -D (Fig. S4, available at http://www.jem
.org/cgi/content/full/jem.20062642/DC1).
VEGF-E cannot rescue lymphatic regression induced 
by blocking VEGF-C and -D
VEGFR-3-Ig was previously shown to inhibit embryonic 
and tumor lymphangiogenesis (17, 20). The lymphatic vessels 
of K14-VEGFR-3-Ig mice regress after the onset of K14 
promoter expression, and the mice lack cutaneous lymphatic 
vessels (17). To study if the lack of lymphatic vessels in these 
mice could be rescued by a VEGFR-2 ligand, we crossed the 
K14-VEGF-E mice with the K14-VEGFR-3-Ig mice. How-
ever, no lymphatic vessels were detected in the skin of the 
compound K14-VEGF-E + K14-VEGFR-3-Ig mice (Fig. 
4 G and not depicted), which indicated that VEGFR-2 signals 
cannot rescue the lymphatic phenotype caused by lack of 
VEGFR-3 signals.
Angiogenesis and lymphangiogenesis in K14-VEGF-E mice 
occur during the fi  rst postnatal weeks
To investigate the lymphatic and blood vascular eff  ects of 
VEGF-E during embryonic development, the back skin of 
staged compound heterozygotic K14-VEGF-E + VEGFR-
3+/LacZ and K14-VEGF-E + VEGFR-2+/LacZ embryos was 
stained for β-galactosidase activity to visualize lymphatic and 
blood vessels. To our surprise, no diff  erences could be found in 
the lymphatic and blood vessel staining patterns or in lymphatic 
sprouting in comparison with the VEGFR-3+/LacZ and -2+/LacZ 
embryos at embryonic day (E) 17.5 (Fig. 5, A–D, arrowheads). 
RT-PCR of RNA extracted from the skin of staged K14-
VEGF-E embryos indicated that VEGF-E is already expressed 
at E14.5 (unpublished data). This indicated that K14-VEGF-E 
had essentially no eff  ect on either the lymphatic or the blood 
vasculature during embryonic development.
To analyze the lymphatic vessel density in the K14-
VEGF-E mice, we counted the number of LYVE-1–positive 
lymphatic vessels in histological sections from 5–7-wk-old 
adult mice as well as from 1-, 7-, and 14-d-old pups. The 
number of lymphatic vessels was not increased in the K14-
VEGF-E mice at any of these time points (unpublished data). 
Also, no considerable diff   erences in the LYVE-1–positive 
lymphatic vessel area were detected between the K14-VEGF-E 
and wild-type littermate mice on postnatal day (P) 1 or P7 
(Fig. 5 E). On day 14, however, the lymphatic vessel area was 
2.2- ± 0.2-fold greater in K14-VEGF-E mice than in the 
wild-type littermates, and this diff  erence was further increased 
to 3.6- ± 0.2-fold in the adult mice. Quantitative RT-PCR 
of RNA extracted from the back skin at day 7 showed no 
diff  erences in the amounts of either VEGF-C or -D expres-
sion between K14-VEGF-E pups and wild-type littermates 
(unpublished data), suggesting that these ligands do not me-
diate the lymphatic phenotype postnatally.
VEGF-E stimulation of lymphatic endothelial cells in 
vitro has previously been shown to increase their proliferation 
(21). To investigate if overexpression of VEGF-E also in-
creased proliferation of lymphatic endothelial cells in vivo, 
we injected the proliferation marker BrdU intraperitoneally 
into pregnant K14-VEGF-E or wild-type mice at E17.5, 
P7 pups, or adult mice. We then counted the number of 
BrdU + LYVE-1 double-positive cells from frozen skin 
sections. Although we could not detect any diff  erences in 
the amount of double-positive BrdU/LYVE-1 cells between 
K14-VEGF-E embryos and wild-type embryos (Fig. 5 F), 
we observed a signifi  cant increase in BrdU/LYVE-1 double-
positive cells in K14-VEGF-E pups at P7 compared with 
Figure 4.  VEGF-E induces lymphatic vessel hyperplasia in the skin 
of transgenic mice. Whole-mount staining for LYVE-1 in the ears of 
K14-transgenic mice expressing the indicated growth factors and wild-type 
mice (wt; A–F). Quantitation of the LYVE-1–positive vessel density in the 
ears of the transgenic mice (G). Results represent the means ± the SD 
of six mice per group. Bar, 150 μm.1436  VEGF RECEPTORS IN LYMPHATIC HYPERPLASIA | Wirzenius et al.
their wild-type littermates. Only a few double-positive cells 
were stained per fi  eld in adult mice, and no diff  erences be-
tween K14-VEGF-E and wild-type mice could be detected. 
These results indicate that the proliferation of lymphatic endo-
thelial cells is increased in the K14-VEGF-E mice compared 
with the wild-type littermates, but that this diff  erence is re-
stricted to the postnatal period, when the lymphatic vessels 
are still actively growing.
Angiogenesis induced by VEGFR-2 stimulation lags behind 
that induced by VEGFR-1 stimulation
We also analyzed the blood vasculature from histological 
sections of 1-, 7-, and 14-d-old pups stained for PECAM-1 
(Fig. S5, available at http://www.jem.org/cgi/content/full/
jem.20062642/DC1). At day 1, the blood vessel area in K14-
VEGF-E mice was not substantially increased as compared 
with wild-type littermates, whereas the blood vessel area was 
increased by 3.2- ± 0.3-fold in K14-PlGF mice and by 3.5- ± 
0.2-fold in K14-VEGF-E + K14-PlGF mice. On P7 and P14, 
the blood vessel area in K14-VEGF-E mice was increased 
by 3.5- ± 0.2-fold and 3.6- ± 0.1-fold, respectively, compared 
with wild-type littermates. This indicates that whereas new-
born K14-PlGF mice already have blood vessel hyperplasia, 
the angiogenic eff  ect of K14-VEGF-E starts during the fi  rst 
postnatal week, and it may in fact precede the onset of lym-
phatic vessel hyperplasia.
Vessel leakage is inhibited in the double-transgenic 
K14-VEGF-E + K14-PlGF mice
Overexpression of VEGF-E via an adeno-associated virus vec-
tor promotes blood vessel leakage (22). K14-PlGF mice also 
show increased vessel permeability (23). As vessel leakage re-
sults in interstitial edema that may provoke lymphatic vessel 
enlargement, we wanted to study in more detail the relation-
ship between edema and lymphatic hyperplasia in the trans-
genic mice. To compare vessel permeability in the transgenic 
mice, we injected high molecular weight FITC-dextran into 
the tail vein and monitored the effl   ux of the dye at diff  erent 
time points. FITC-dextran leaked out much more rapidly 
from the vessels of the K14-VEGF-E and K14-PlGF mice 
compared with the K14-VEGF-E + K14-PlGF mice (Fig. 
6, A–D). We also injected Evans blue dye into the tail vein of 
the transgenic mice and their wild-type littermates and moni-
tored its extravasation. Spectrophotometric quantifi  cation of the 
dye indicated that although both K14-VEGF-E and K14-PlGF 
exhibited increased vessel permeability, the K14-VEGF-E + 
K14-PlGF mice had comparatively reduced vessel permeabil-
ity (Fig. 6 E). The results agreed with those from the FITC-
dextran experiments, and they indicate that PlGF, possibly by 
stimulating VEGFR-1 homodimer formation, can at least par-
tially block the increased capillary permeability induced by 
VEGF-E through VEGFR-2 homodimer formation.
Correlation of blood fl  ow with vascular leakage 
in the transgenic mice
Using a laser Doppler fl   owmeter, we measured ear tissue 
blood fl  ow in the transgenic mice at 5 wk of age. Both the 
K14-VEGF-E and K14-PlGF mice had considerable in-
creased blood fl  ow (fold increase of 3.5 ± 0.2 and 3.9 ± 0.1, 
respectively) compared with the wild-type littermates (Fig. 
6 F). To our surprise, the K14-VEGF-E + K14-PlGF mice 
showed only 2.0- ± 0.1-fold increased blood fl  ow compared 
with the wild-type littermates, even though these mice have 
an increased density of blood vessels compared with the sin-
gle transgenic mice (Fig. S5 and not depicted).
To investigate if the decreased blood fl  ow in K14-VEGF-
E + K14-PlGF mice was correlated with an increase in the 
smooth muscle cell (SMC) coating around the blood vessels, 
we measured the ratio of smooth muscle α-actin (SMA)–
positive cells to PECAM-1 positive cells from frozen sections 
of the skin. As shown by representative images and ratio 
quantifi  cation, the SMC layer around the blood vessels in 
Figure 5.  The lymphatic and blood vascular phenotypes in K14-
VEGF-E mice occur postnatally. (A and B) Skin lymphatic vessels of 
K14-VEGF-E + VEGFR-3+/LacZ compound heterozygote and VEGFR-3+/LacZ 
(wt) embryos were analyzed by β-galactoside staining at E17.5. Note the 
similar degree of lymphatic vessel sprouting (arrowheads). Embryonic skin 
blood vessels of a K14-VEGF-E + VEGFR-2+/LacZ compound heterozygote 
and VEGFR-2+/LacZ mice were analyzed by β-galactoside staining at E17.5 
(C and D). (E) Comparison of the lymphatic vessel areas of 1-, 7-, and 14-d-
old pups and adult K14-VEGF-E mice. (F) Comparison of BrdU + LYVE-1 
double-positive cells in E17.5 embryos, P7 pups, and adult K14-VEGF-E 
mice. The asterisks indicate signifi  cantly increased vessel density areas. 
*, P < 0.05. Results represent the means ± the SD of six embryos/mice 
per group. Bars: (A and B) 500 μm; (C and D) 200 μm.JEM VOL. 204, June 11, 2007  1437
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K14-VEGF-E + K14-PlGF mice appeared to be denser than 
in single transgenic and wild-type mice (Fig. 6, G–K). This 
suggested that the K14-VEGF-E + K14-PlGF mice have a 
thicker SMC layer around the blood vessels, and hence de-
creased blood fl  ow and capillary exchange rate compared with 
the single-transgenic K14-VEGF-E and K14-PlGF mice. In 
contrast, K14-VEGF165 mice did not show enhanced SMC 
coverage over that seen in wild-type littermates or K14-
VEGF-E or K14-PlGF single transgenic mice (unpublished 
data). Because the eff  ects of   VEGF are mostly mediated by 
VEGFR-2, and because K14-VEGF165 mice have an en-
hanced vessel leakage, probably caused by a loosely attached 
SMC layer around the arteries (24), our results suggest that 
PlGF-induced VEGFR-1 homodimers play a role in the re-
duction of   VEGF-E/VEGFR-2–mediated leakiness.
D  I  S  C  U  S  S  I  O  N 
We have analyzed the roles of VEGF receptors in lymphan-
giogenesis by using adenoviral and transgenic overexpression 
of VEGF family members in mouse skin, combined with 
the use of antibodies blocking specifi  c VEGF receptors. In 
particular, overexpression of PlGF and VEGF-E allowed 
specifi  c stimulation of VEGFR-1 and -2. Our data shows 
that stimulation of VEGFR-2 induces hyperplasia of the 
lymphatic vessels, but very few vessel sprouts, in postnatal 
mice. On the other hand, we could not detect any lymphatic 
phenotype when only the VEGFR-1 was activated by over-
expression of PlGF in the skin. This indicates that the 
  lymphatic vascular eff  ects induced by overexpression of VEGF 
as seen by us and others (12, 13), are indeed mediated mainly 
via VEGFR-2.
VEGFR-2 expression has been shown to be high in the 
endothelial tip cells of blood vessels, which, through their 
  fi  lopodia, sense the VEGF gradient to guide blood vessel 
sprouting (16). We show that the sprouting mechanism of the 
lymphatic vessels was not dependent on VEGFR-2 in adults. 
Although the mouse VEGF isoform promoted some lym-
phatic vessel sprouting, the human isoform that binds to the 
Figure 6.  Vessel leakage is inhibited in double-transgenic K14-
VEGF-E + K14-PlGF mice. Immunofl  uorescent images of mouse ears 
10 min after FITC-dextran injection (A–D). Both K14-VEGF-E (A) and K14-
PlGF mice (B) display increased permeability (asterisk) and leakiness of the 
vessels in comparison to wild-type littermates (D). In the double K14-
VEGF-E + K14-PlGF mice, much of the leakage is halted (C). Quantitation 
of blood vessel leakage 10 min after dye injection in the modifi  ed Evans 
blue permeability assay (E). Laser Doppler fl  owmetric analyses for blood 
fl  ow in the ears of the transgenic mice (F). Immunofl  uorescence staining 
for PECAM-1 (green) and SMA (red) in the skin of transgenic mice (G–J). 
Note the thickened SMC layer around the blood vessel in the K14-VEGF-E + 
K14-PlGF mice (I). Quantitation of the SMA/PECAM-1 ratio in the skin 
of transgenic mice (K). The asterisks indicate signifi  cantly increased vessel 
leakage (E), fl  ow (F), or SMA/PECAM-1 ratio (K). *, P < 0.05; **, P < 0.01. 
Results represent the means ± the SD of six mice per group. Bars: (A–D) 
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same receptors did not. However, both isoforms induced 
enlargement of lymphatic vessels and proliferation of blood 
vessels. Furthermore, overexpression of the VEGFR-2–specifi  c 
ligand VEGF-E did not lead to sprouting of the lymphatic 
vessels, but instead to circumferential growth and the sprout-
ing of the lymphatic vessels induced by adenoviral VEGF-C, 
which could not be blocked with neutralizing   antibodies 
against VEGFR-2. These results suggest that the sprouting 
mechanisms of lymphatic vessels in adults do not rely on 
VEGFR-2, and thus diff  er from those of the blood vessels.
Surprisingly, VEGF-E did not induce changes in the 
lymphatic vasculature during embryonic development. Al-
though VEGF-E stimulated lymphatic vessel enlargement in 
postnatal mice, we did not detect increased numbers of lym-
phatic vessels in the K14-VEGF-E mice at any age analyzed. 
This indicates that signaling through VEGFR-2 does not 
induce lymphangiogenesis during embryonic development, 
but its eff  ects become apparent during the postnatal period 
upon maturation of the blood and lymphatic vessels. As with 
the adenovirus vectors, we also detected circumferential lym-
phatic vessel hyperplasia without additional sprouting in 
the transgenic mice after 1 wk of postnatal growth. One pos-
sibility was that at least some of the hyperplasia was a second-
ary eff  ect resulting from the vascular leakage promoted by 
VEGF-E overexpression. The lymphatic hyperplasia started 
after the eff  ects of VEGF-E in the blood vessels became 
apparent, and both the vascular leakage and the lymphatic 
hyperplasia could be reduced by PlGF overexpression that 
apparently reduced blood flow via the increased coating 
of small vessels by SMCs. However, from additional ex-
periments, we learned that vascular leakage alone was not 
  suffi   cient for the hyperplasia, as the lymphatic vessels of 
the K14-PlGF mice appeared to be normal, although their 
blood vessels were even leakier than in the K14-VEGF-E 
mice. We cannot currently explain the late onset of the ef-
fects of the K14-VEGF-E transgene, despite its high-level 
expression starting during the embryonic period. It may be 
speculated that in vivo particular pericellular matrix proteins 
and integrins are required for specifi  c  VEGFR-2  activa-
tion by VEGF-E, and that they are not present until later 
in development. Importantly, we also found that adenoviral 
coexpression of PlGF inhibits VEGF-E-induced, but not 
VEGF-C156S–induced, lymphatic hyperplasia (this study 
and unpublished data).
We also found that VEGF-E overexpression was not 
able to rescue the lymphatic regression induced by blocking 
VEGF-C and -D (the VEGF-C/D trap). This result indi-
cates that VEGFR-2 cannot substitute for VEGFR-3 sig-
nals during the onset of lymphangiogenesis. In accordance 
with these data, treatment with AdVEGFR-2-Ig does not 
aff  ect the postnatal development of lymphatic vessels (25). 
VEGFR-3 was expressed strongly in lymphatic capillaries, 
and it was internalized into the lymphatic endothelial cells 
after adenoviral VEGF-C stimulation, but not after VEGF-E 
stimulation, indicating that VEGF-E does not lead to sig-
naling via this receptor. VEGFR-2 was expressed weakly in 
lymphatic capillaries and more strongly in collecting lym-
phatic vessels in wild-type mice. The fact that essentially no 
VEGF-E–induced changes were observed in the collecting 
lymphatic vessels or lymph nodes was surprising considering 
the strong constitutive VEGFR-2 expression in these vessels. 
However, VEGFR-2 was internalized in both types of ves-
sels upon   AdVEGF-E or -C transduction, indicating that the 
receptor was functional.
In conclusion, we show here that overexpression of a 
VEGFR-2–specifi  c ligand induces circumferential hyper-
plasia of the lymphatic vessels in adult, but not in embryonic, 
skin. However, VEGFR-2 activation is not suffi   cient for the 
generation of new lymphatic vessels, and it was not able to 
rescue the lymphatic regression induced by blocking the 
VEGFR-3 ligands VEGF-C and -D. These results specify the 
contribution of the diff  erent VEGFR pathways to lymphan-
giogenesis and reveal previously unknown postnatal changes 
that occur in the sensitivity of both blood and lymphatic ves-
sels toward VEGF family ligands.
MATERIALS AND METHODS
Cell stimulation and Western blot analysis. PAE cells stably overex-
pressing VEGFR-2 (26) or -3 (17) were starved overnight in serum-free 
medium and incubated for 20 min with soluble VEGFR-2-Ig or VEGFR-
3-Ig (357-kD and 349-F4; R&D Systems) fusion proteins or rat monoclonal 
antibodies against human VEGFR-2 (1121B; a gift from B. Pytowski, Im-
Clone Systems, New York, NY) at a concentration of 1 μg/ml. The cells 
were stimulated for 10 min with recombinant VEGF-E (27) or -C (28) at the 
indicated concentrations, washed with PBS, and lysed in ice-cold PLCLB 
lysis buff  er (150 mM NaCl, 5% glycerol, 1% Triton X-100, 1.5 M MgCl2, 
and 50 mM Hepes, pH 7.5) containing 2 mM sodium vanadate, 2 mM 
PMSF, 10 μg/ml leupeptin, and 0.07 U/ml aprotinin. Clarifi  ed lysates were 
immunoprecipitated with antibodies against 2 μg/ml VEGFR-3 (9D9f9 
[29]) or 2 μg/ml VEGFR-2, separated by SDS-PAGE, and transferred to a 
nitrocellulose fi  lter. Detection was performed with phosphotyrosine-specifi  c 
antibodies (clone 4G10; Millipore) and an enhanced chemiluminescence 
detection system (Pierce Chemical Co.). Antibodies against VEGFR-2 
(C-1158; Santa Cruz Biotechnology) or -3 were used for detection of 
VEGFR-2 and -3 in the Western blot, respectively.
Generation and in vitro analysis of recombinant adenoviruses. Full-
length VEGF-E cDNA (GenBank accession no. AF106020) was cloned into 
the pAdapt vector, and the adenovirus was produced as previously described 
(30). The adenoviruses encoding VEGF164, VEGF165, VEGF-C, VEGFR-
3-Ig, and nuclear-targeted β-galactosidase (LacZ) were constructed and pro-
duced as previously described (13, 30–32). Analysis of protein expression was 
carried out as previously reported (32).
In vivo use of the viral vectors. 2.5 × 108 PFU of recombinant adeno-
viruses encoding VEGF-C, VEGF-E, VEGF164, VEGF165, or LacZ were 
injected intradermally into 4–6-wk-old female NMRI nu/nu mice (Harlan). 
The skin was analyzed 4 d later. For inhibition experiments, 109 PFU of 
VEGFR-3-Ig or LacZ adenoviruses were injected intravenously 3 d before 
the ligand-encoding adenoviruses.
For sprouting inhibition experiments, the mice were injected intraperi-
toneally with 600 μg of mF4-31C1, which is a rat monoclonal antibody 
against mouse VEGFR-3 (33), DC101, which is a rat monoclonal antibody 
against mouse VEGFR-2 (34), or rat IgG every second day in a volume of 
200 μl. 1 d later, 2.5 × 108 PFU of recombinant adenoviruses encoding 
VEGF-C, VEGF-C156S, VEGF-E, or LacZ were injected intradermally 
into the ears of the same mice. The skin was analyzed 3–4 d later.JEM VOL. 204, June 11, 2007  1439
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Transgenic mice. The K14-VEGF-E, K14-PlGF, K14-VEGF-C156S, 
K14-VEGF-C, K14-VEGFR-3-Ig, K14-VEGF165, VEGFR-3+/LacZ, and 
VEGFR-2+/LacZ mice were previously described (11, 17, 19, 23, 24, 35–37). 
The Provincial State Offi   ce of Southern Finland approved all experiments 
involving mice, and they were performed in accordance with institu-
tional guidelines.
Analysis of lymphatic and blood vessels. Whole-mount staining was 
performed as previously published (15). Blood and lymphatic vessels were 
stained with rabbit antiserum against LYVE-1 (38), α-hamster monoclonal 
anti–mouse PECAM-1 antibody (clone 2H8, MAB-13982Z; CHEMICON 
International, Inc.), α-goat polyclonal anti–VEGFR-2 antibody (AF644; 
R&D Systems), or α-goat polyclonal anti–mouse VEGFR-3 antibody 
(AF743; R&D Systems), followed by appropriate fl  uorochrome-conjugated 
secondary antibody (Alexa Fluor 488 or 594 [Invitrogen] or FITC [Jackson 
ImmunoResearch Laboratories]). Frozen sections were fi  xed with −20°C 
acetone, incubated with anti-LYVE-1, the hamster monoclonal antibody 
against PECAM-1 (CHEMICON International, Inc.), a rat monoclonal an-
tibody against CD11b (BD Biosciences), or mouse anti–SMA-Cy3 (Sigma-
Aldrich), followed by the appropriate fl  uorochrome-conjugated secondary 
antibodies and analysis with a compound fl  uorescent microscope (Zeiss 2; 
Carl Zeiss MicroImaging, Inc.; 10× objective/NA 0.30), or a confocal 
microscope (Zeiss LSM 510; 20× objective/NA 1.3 and 40× objective/
NA 1.4). Three-dimensional projections were digitally constructed from 
confocal z stacks.
Paraffi   n sections were stained with a rabbit antibody against LYVE-1 
and a rat anti–monoclonal antibody against PECAM-1 (BD Biosciences) 
using the tyramide signal amplifi  cation kit (PerkinElmer). Lymphangiography 
and visualization of blood vessels with FITC-dextran was performed as pre-
viously described (22, 32). Quantitation of the lymphatic sprouts and the 
area covered by lymphatic or blood vessels in the skin was performed as pre-
viously described (25). The area covered by lymphatic or blood vessels in the 
skin was quantifi  ed from photomicrographs of LYVE-1– or PECAM-1–
stained sections (6 photomicrographs/mouse, and 6 mice of each genotype 
at each time point) using the Image-Pro Plus program (Media Cybernetics). 
All statistical analyses were performed using the unpaired Student’s t test. 
A P value of <0.05 was considered statistically signifi  cant.
𝗃-Galactosidase staining of vessels. Staged embryos of the compound 
K14-VEGF-E  + VEGFR-2+/LacZ and K14-VEGF-E + VEGFR-3+/LacZ 
mice were dissected, fi  xed in 0.2% glutaraldehyde, and stained with X-gal 
(Sigma-Aldrich) for β-galactosidase activity at 37°C.
BrdU incorporation and immunostaining. 20 mM BrdU in PBS was 
injected intraperitoneally at a volume of 20 μl/g into adult mice, P7 
pups, or pregnant mice at E17.5. Mice were sacrifi  ed 4 h later, and frozen 
sections from the skin were stained with a monoclonal rat anti-BrdU anti-
body   (Abcam Ltd.).
RT-PCR. RNA extracted from the skin of staged K14-VEGF-E embryos 
and their wild-type littermates was reverse transcribed using oligo-dT 
(Boehringer) and Superscript II reverse transcriptase (Invitrogen). PCR anal-
ysis using a pair of primers specifi  c for VEGF-E or β-actin primers was per-
formed as previously published (22).
Quantitative RT-PCR. RNA was extracted from K14-VEGF-E and wild-
type littermate pups at P7, and quantitative PCR reactions were performed as 
previously described (25) with the DyNAmo HS SYBR Green qPCR kit 
(Finnzymes) using the ABI 7500 SDS real-time PCR instrument (Applied 
Biosystems). The oligonucleotide primers used are as follows: 5′-C  A  C  A  G  T  G-
T  C  A  G  G  C  A  G  C  T  A  A  C  -3′ and 5′-T  C  C  A  C  A  G  A  C  A  T  C  A  T  G  G  A  A  T  C  -3′ for 
VEGF-C; and 5′-C  T  T  G  C  T  G  G  A  A  C  A  G  A  A  G  A  C  C  A  -3′ and 5′-C  T  C  T  G  A-
G  G  A  C  T  G  G  A  A  G  C  T  G  T  -3′ for VEGF-D, as well as 5′-A  C  A  A  C  T  T  T  G  G  C  A-
T  T  G  T  G  G  A  A  -3′ and 5′-G  A  T  G  C  A  G  G  G  A  T  G  A  T  G  T  T  C  T  G  -3′ for GAPDH. 
The expression of the genes was normalized to GAPDH expression.
Measurement of vascular permeability and tissue blood fl  ow. A modi-
fi  ed Evans blue permeability assay was performed as previously described 
(32). Microcirculation was measured from the base of the ear by a HL-N1451 
Flowprobe (Transonic Systems, Inc.) connected to a laser Doppler fl  ow-
meter (model BLF21; Transonic Systems, Inc.).
Online supplemental material. Fig. S1 shows ligand-dependent VEGFR-2 
and -3 phosphorylation and its inhibition by antibodies. Fig. S2 shows in-
ternalization of VEGFR-2 and -3 upon ligand stimulation in the lymphatic 
capillaries. Fig. S3 shows collecting lymphatic vessels and lymph node vascu-
larity in K14-VEGF-E mice. Fig. S4 shows a CD11b staining of the skin of 
the diff  erent transgenic mice. Fig. S5 shows PECAM-1 staining of the skin 
of transgenic mice at diff  erent ages. The online version of this article is avail-
able at http://www.jem.org/cgi/content/full/jem.20062642/DC1.
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